• RANJODH JEET SINGH Department of Pharmacology, Maharishi Markandeshwar Institute of Medical Sciences and Research, Maharishi Markandeshwar Deemed to be University, Mullana, Haryana, India.



Cardiovascular disease, Hypertension, Blood pressure, Systolic blood pressure, Beta-blockers, Angiotensin receptor blockers, Heart rate


Aim and Objectives: The aim of the study was to compare the efficacy of Atenolol and Olmesartan in Stage-1 hypertension (HTN), and the adverse effect profile of Atenolol and Olmesartan in Stage-1 HTN.

Methods: A prospective, randomized, open, and parallel study was carried out in 100 patients attending the outpatient department of General Medicine Department MMIMSR, Mullana, Ambala, India with Stage -1 HTN according to joint national committee VII. The patients were randomly divided into two groups to receive Tab. Atenolol 50 mg od (Group A, n=50) and Tab. Olmesartan medoxomil 20 mg (Group B, n=50) od for a total period of 12 weeks with regular follow up every 2 weeks from the baseline. At each visit, blood pressure (BP), heart rate, and adverse effects were evaluated. Laboratory investigations were carried out at baseline and end of the study period. p<0.005 was considered statistically significant.

Results: Atenolol and Olmesartan medoxomil both significantly reduce BP and heart rate (p<0.005). Olmesartan medoxomil is more efficacious in reducing BP.

Conclusion: Olmesartan medoxomil is a better choice for Stage -1 HTN between the two drugs as it leads to a greater decrement in BP.


Download data is not yet available.

Author Biography

RANJODH JEET SINGH, Department of Pharmacology, Maharishi Markandeshwar Institute of Medical Sciences and Research, Maharishi Markandeshwar Deemed to be University, Mullana, Haryana, India.

assistant professor, department of pharmacology.


Elkum N, Al-Arouj M, Sharifi M, Behbehani K, Bennakhi A. Cardiovascular disease risk factors in the South Asian population: A cross-sectional study. Diabet Med 2014;31:531-9. DOI:

Ismail J, Jafar TH, Jafary FH, White F, Faruqui AM, Chaturvedi N. Risk factors for non-fatal myocardial infarction in young South Asian adults. Heart 2004;90:259-63. DOI:

Gupta R, Misra A, Vikram NK, Kondal D, Gupta SS, Agrawal A, et al.. Younger age of escalation of cardiovascular risk factors in Asian Indian subjects. BMC Cardiovasc Disord 2009;9:28. DOI:

Stafylas PC, Sarafidis PA. Carvedilol in hypertension treatment. Vasc Health Risk Manag 2008;4:23-30. DOI:

Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al.. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC report. JAMA 2003;289:2560-72. DOI:

Bundgaard M, Jarbol DE, Paulsen MS, Jacobsen JL, Pedersen ML. Prevalence of the use of antihypertensive medications in Greenland: A study of quality of care amongst patients treated with antihypertensive drugs. Int J Circumpolar Health 2012;71:103402. DOI:

Lawes CM, Hoorn VS, Rodgers A. Global burden of blood-pressure-related disease, 2001. Lancet 2008;371:1513-28. DOI:

Patricia MK, Megan BS, Kristi R, Paul M, Paul KW, Jiang H. Global burden of hypertension: Analysis of worldwide data. Lancet 2005;365:217-23. DOI:

Thakur K, Malhotra P, Walia T, Kumar R. Health awareness and treatment compliance of high blood pressure among women in periurban colony of Chandigarh, India. Indian Med Assoc 1999;97:217-9.

Gupta R. Trends in hypertension epidemiology in India. J Hum Hypertens 2004;18:73-8. DOI:

Hamon M, Loncew DA. Overview of circulation; medical, physics of pressure flow and resistance. In: Guyton Medical Physiology Editors, Guyton and John Hall. 12th ed. Philadelphia, PA: Elsevier; 2011. p. 166.

Carretero OA, Oparil S. Essential hypertension. Part I: Definition and etiology. Circulation 2000;101:329-35. DOI:

James PA, Oparil S, Carter BL, Cushman WC, Dennison C. Report from the panel members appointed to the eighth joint national committee (JNC 8). JAMA 2014;311:507-20. DOI:

Franklin SS. Is there a preferred antihypertensive therapy for isolated systolic hypertension and reduced arterial compliance. Curr Hypertens Rep 2000;2:253-59. DOI:

Ehret GB, Munroe PB, Rice KM, Bochud M, Johnson AD, Chasman DI, et al.. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature 2011;478:103-9. DOI:

Haslam DW, James WP. Obesity. Lancet 2005;366:1197-209. DOI:

Jürgens G, Graudal NA. Effects of low sodium diet versus high sodium diet on blood pressure, renin, aldosterone, catecholamines, cholesterols, and triglyceride. Cochrane Database Syst Rev 2004;1:CD004022. DOI:

Dahl LK. Possible role of salt intake in the development of essential hypertension. In: Bock KD, Cotlier PT, editors. Essential Hypertension. Berlin: Springer Verlog; 1960. p. 53-6. DOI:

Reeta KL, Khullar M, Kashap M, Pandhi P, Uppal R. Effect of oral magnesium supplementation on blood pressure, platelet aggregation and calcium handling in deoxycortisterone acetate induced hypertention in rats. J Hypertens 2000;18:919-26. DOI:

Tobian L, Lange J, Ulm K, Wold L, Iwai J. Potassium reduces cerebral hemorrhage and death rate in hypertensive rats even when blood pressure is not lowered. Hypertension 1985;7:110-4. DOI:

Coerstein HC, Yusef S. Dysglycemia and rate of cardio vascular disease. Lancet 1996;347:946-50.

Labounty TM, Gomez MJ, Achenbach S, Al-Mallah M, Berman DS, Budoff MJ, et al.. Body mass index and the prevalence, severity, and risk of coronary artery disease: An international multicentre study of 13,874 patients. Eur Heart J Cardiovasc Imaging 2013;14:456-63. DOI:

Hoffner SM, Mykkanen LK, Laokso M. Insulin resistance, body fat distribution and sex hormones in men. Diabetes 1994;43:212-9. DOI:

Sowers JR. Modest weight gain and the development of diabetes: Another prospective ANN Intern Med 1995;122:548-9. DOI:

Singaru D, Greco D, Scarpitla AM. Blood pressure insulin secretion and resistance in non-hypertensive obese female subject. Int J Obese 1995;19:1610-3.

Bakris GL, Weir MR, Sowers JR. Therapeutic challenges in obese diabetic patients with hypertension. Am J Med 1996;101:533-46. DOI:

Scala May C, Laparte R, Dorman J. Insulin dependent diabetes mellitus mortality: The risk of cigarette smoking. Circulation 1990; 82:37-43. DOI:

Fornage M, Amas CL, Kardia S. Variation in the region of ACE gene influences inter individuals differences in blood pressure levels in young white males. Circulation 1991;97:1773-9. DOI:

O’Donnell CJ, Partner KL, Larson MG. Evidence for association and genetic linkage of the ACE locus with hypertension and blood pressure in men but not in women in the Framingham heart study. Circulation 1998;97:1966-76. DOI:

Cerosola G, Cotlane S, D’Lgnato G. Sympathetic activity in borderline and established hypertension in the elderly. J Hypertens 1988;1:555-8.

Rosenman RH, Brand RJ, Schaltz RT. Multivariate predictions of coronary heart disease during the 8.5 years follow up in the western collaborative group study. Am J Cardiol 1976;37:903-12. DOI:

Davi G, Caltalons I, Averna M. Thromboxane biosynthesis and platelet function in Type II Diabetes Mellitus. N Eng J Med 1990;322:1768-74. DOI:

Goligorsky MS. Endothelial cell dysfuntion and nitric oxide synthase. Kidney Int 2000;58:1360-76. DOI:

Ramirez LC, Arauz-Pachaco C, Lackner C. Lipoprotien (a) levels in diabetes mellitus: Relation to metabolic control. Ann Intern Med 1992;117:42-47. DOI:

Landing K, Born LT, Smith U, Elevated fibrinogen and plasminogen activator inhibitor (PAI-I)in hypertension are related to metabolic risk factors for cardiovascular disease. Intern Med 1990;227:273-8. DOI:

Boers GH, Tribels FJ, Fowler B. Heterozygosity for homocysteinuria in premature peripheral and cerebral occlusive arterial disease. N Engl J Med 1985;313:709-14. DOI:

Dluhy RG, Williams GH. Endocrine hypertension. In: Wilson JD, Foster DW, Kronenberg HM, editors. Williams Textbook of Endocrinology. 9th ed. Philadelphia, PA: WB Saunders Publication; 1998. p. 729-49.

Kotchen TA. Hypertensive vascular disease. In: Longo D, Fauci A, Kasper D, Hauser S, Jameson J, Loscalzo J, editors. Harrison’s Principles of Internal Medicine. 18th ed. Harvard: McGraw Hill Publication; 2011. p. 2042-59.

Conway J. Hemodynamic aspects of essential hypertension in humans. Physiol Rev 1984;64:617-60. DOI:

Navar LG. Counterpoint: Activation of the intrarenal renin-angiotensin system is the dominant contributor to systemic hypertension. J Appl Physiol 2010;109:1998-2000. DOI:

Ching N. Yellow Emperor’s Classic of Internal Medicine. Books 2-9, Published between 2698 and 2598 B.C; 2006.

Korotkoff NS. Izvestiya Imperatorskoi Voenno-Meditsinskoy Akadernii. Rep Imper MIL Med Acca St Peterburg 1905;11:365-7.

Freis ED. In: Laragh JH, Brenner BM, editors. Hypertension, Pathophysiology Diagnosis and Management. 2nd ed. New York: Raven Press; 1995. p. 2741-51.

Strickler CW. Significance of Hypertension. South Med J 1917;10:191-4. DOI:

White PD. Heart Disease. 2nd ed. New York: MacMillan Co.; 1937. p. 326.

Moser M. Evolution of the treatment of hypertension from the 1940s to JNV V. Am J Hypertens 1997;10:2S-10S. DOI:

VA Cooperative Study Group. Effects of treatment on morbidity in hypertension Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA 1967;202:1028-34. DOI:

Hamdy RC. Hypertension: A turning point in the history of medicine and mankind. Southern Med J 2001;94:1045-47. DOI:

Report of the joint national committee on detection, evaluation, and treatment of high blood pressure. A cooperative study. JAMA 1977;237:255-61. DOI:

ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to Angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The antihypertensive and lipid-lowering treatment to prevent heart attack trial. JAMA 2002;288:2981-97. DOI:

Oparil S. High blood pressure in: Goldman L, Bennett JC, editors. Cecil Textbook of Medicine. Philadelphia, PA: WB Saunder; 2000. p. 718-20.

Sacks FM, Svetkey LP, Vollman WM, Appel LJ, Bray GA, Harsh D, et al.. Effects of blood pressure of reduced dietary Na and dietary approaches to stop hypertension (DASH) diet. N Engl J Med 2001;344:3-10. DOI:

Cook NR, Cohen J, Hebert PR. Implications of small reduction in diastolic blood pressure for primary prevention. Arch Intern Med 1995;155:701. DOI:

Moser M. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997;157:2413-46. DOI:

Cobe MC, Bockarich MA, Srivastava K, Young DB. Potassium inhibits free radical formation. Hypertension 1994;24:77-82. DOI:

Sempos C, Copper R, Kovor MG. Dietary calcium and blood pressure in national health nutrition examination survey I and II. Hypertension 1986;18:1067-74. DOI:

McCorron DA. Calcium and magnesium nutrition in human hypertension. Ann Inter Med 1983;198:800-5. DOI:

Trial of Hypertension Prevention Collaborative Research Group. Effect of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high normal blood pressure. The trial of hypertension prevention, phase II. Arch Inter Med 1997;157:657-67. DOI:

Cushman WC, Cutlar JA, Hanna E. The prevention and treatment of hypertension study (PATHS). Arch Intern Med 1998;158:1197-207. DOI:

Isles C, Brown JJ, Ceimming AM. Excess smoking in malignant phase hypertension. BMJ 1979;1:579-81. DOI:

Rosenberg L, Kaufman DW, Helmrich SP, Shapiro S. The risk of myocardial infarction after quitting smoking in men under 55 years of age. N Engl J Med 1985;313:1511-4. DOI:

Blair S, Goodyear N, Gibbons L. Physical fitness and incidences of hypertension in healthy normotensive men and women. JAMA 1984;252:487-90. DOI:

Stapleton MP. Sir James Black and propranolol. The role of the basic sciences in the history of cardiovascular pharmacology. Texas Heart Inst J 1997;24:336-42.

Brogden RN, Heel RC, Speight TM, Avery GS. Metoprolol: A review of its pharmacological properties and therapeutic efficacy in hypertension and angina pectoris. Drugs 1977;14:321-48. DOI:

Barreras A, Turner CG. Angiotensin II receptor blockers. Proc Baylor Univ Med Centre 2003;16:123-6. DOI:

Jackson TW, George B, Tom G, Larry YA, Lawrence JA, Jeanne C, et al.. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease. J Am Med Assoc 2002;288:2421-31. DOI:

Rasmussen S, Arnung K, Eskildsen PC, Nielsen PE. A comparative study of atenolol and Metoprolol in the treatment of hypertension. Br J Clin Pharmacol 1981;12:887-91. DOI:

Freytag F, Schelling A, Meinicke T, Deichsel G. Comparison of 26-week efficacy and tolerability of telmisartan and atenolol, in combination with hydrochlorothiazide as required, in the treatment of mild to moderate hypertension: A randomized, multicenter study. Clin Ther 2001;23:108-23. DOI:

Van Miegham W. A multicentre, double blind, efficacy, tolerability and safety study of the oral angiotensin II antagonist olmesartan medoximil versus atenolol in patients with mild to moderate essentialhypertension. J Hypertens 2001;19 Suppl 2:152.

Alcocer L, Fernández-Bonetti P, Campos E, Ruiz RO, Bahena J, de la Fuente JJ, et al.. Clinical efficacy and safety of telmisartan 80 mg onc daily vs. atenolol 50 mg once daily in patients with mild-to-moderate hypertension. Int J Clin Pract Suppl. 2004;145:35-9. DOI:

Puchler K, Laeis P, Gunther A. Safety, Tolearability and Efficacy of New Oral Angiotensin II (AT 1) Receptor Antagonist Olmesartan Medoxomil with those of Atenolol in Patients with Moderate to Severe Hypertension under Continous Treatment with Hydrochlorothiazide; ???.

Pollare T, Lithell H, Selinus I, Berne C. Sensitivity to insulin during treatment with atenolol and metoprolol: A randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. Br Med J 1989;298:1152-7. DOI:

Sahana GN, Sarala N, Kumar TN, Lakshmaiah V. A comparative study of atenolol versus nebivolol on blood pressure and heart rate on essential hypertensive patients. Indian J Pharmacol 2010;42:401-5. DOI:

Fonseca VA. Effects of beta-blockers on glucose and lipid metabolism. Curr Med Res Opin 2010;26:615-29. DOI:

Smith J, Ferland A, Methot J, Brassard P, Lacroixs S, Poirier P, et al. The beta-1 adrenergic-antagonist, atenolol decreases acylation stimulating protein, exercise capacity and plasma free fatty acids in men with Type 2 diabetes. Nutr Metab Cardiovasc Dis 2012;22:495-502. DOI:



How to Cite

SINGH, R. J. “ANTIHYPERTENSIVE PHARMACOTHERAPY IN HYPERTENSIVE PATIENTS AT A TERTIARY CARE TEACHING HOSPITAL AND MEDICAL COLLEGE IN INDIA”. Asian Journal of Pharmaceutical and Clinical Research, vol. 14, no. 11, Nov. 2021, pp. 41-47, doi:10.22159/ajpcr.2021.v14i11.42728.



Original Article(s)